Ceres Demeter Invests 150 Million Pesos in Cordoba in Innovations for Agriculture

Ceres Demeter, a research and development (R&D) company of biological products for companies in the agricultural sector, announced an investment of 150 million pesos for the expansion and modernization of its R&D laboratories and its formulating plant, located in the city of Río Cuarto.

“This investment will help us consolidate the growth plans we have been sustaining and thus manage to cover the current demand for bioinputs to increase our development capacity tenfold this season. This will enable us to supply our main agroindustrial customers, thus strengthening their biotechnology product portfolios,” said Sergio Bonansea, CEO of the company.

Currently, the R&D laboratories and the company’s formulating plant cover an area of 300 square meters and with this investment will increase to a total of 700 square meters. In the same line, the company plans to incorporate around 20 workers to its team in the next two years.

Read more about Ceres Demeter and find the latest business news in the world with the Born2Invest mobile app.

The main objective of the investment plan is to develop new innovation projects and then transfer them to companies in the agricultural sector to be marketed around the world

Among them, it is worth mentioning that the company recently received from the National University of Córdoba and the National Institute of Agricultural Technology the exclusive license for the development and commercialization of a biopolymer to be applied to peanuts as a protective adhesive.

“The growth in development and formulation capacity will allow our team to generate greater competitiveness in the provision of new microbial technologies, with greater speed and final quality,” added Christopher Kilmurray, CSO of the company.

In terms of the market, Ceres Demeter is expanding its business in Argentina, Brazil and the United States as a strategic partner of companies in the agricultural sector, to which it provides the development and formulation of customized biological solutions.

“Our main objective is to develop and transfer biological solutions to companies in the agricultural sector. We are the link between science and agribusiness,” Kilmurray emphasized.

Part of the investment for the expansions was granted by the Ministries of Production and Science and Technology of the Nation, within a plan to “enhance the competitiveness initiatives of companies with high added value and innovation”.

The company also received support from the Government of Córdoba to develop an energy efficiency program, in line with one of its fundamental pillars and its commitment to reducing its carbon footprint and producing safe food.

Ceres Demeter will position itself as Industry 4.0 by being able to offer solutions focused on interconnectivity, automation, and real-time data, as it will become a fully automated plant that will enable remote monitoring of R&D as well as production processes.

“New technologies will allow us international competition and open the door to new foreign markets with biotech products applied to agriculture from Argentina. At Ceres Demeter we transform knowledge into biotechnological solutions with global impact,” Bonansea concluded.

The company was created in 2009 and its mission is to build bridges between science and agribusiness and bring microbiology from Argentina to the world.

Its team is made up of 28 collaborators and it has a formulation plant in the city of Río Cuarto.

__

(Featured image by Didgeman via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in COMERCIO Y JUSTICIA, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.